Ratings Albemarle Corporation

Equities

ALB

US0126531013

Real-time Estimate Cboe BZX Other stock markets 10:20:19 2024-05-17 am EDT			5-day change	1st Jan Change
132.1 ^USD	+2.28%		+0.81%	-9.56%

May. 16	Chile to open calls for preferential pricing on lithium in second half of 2024	RE
May. 16	Albemarle Secures Option to Double Chile Lithium Mining Production Quota	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is in debt and has limited leeway for investment
With a 2024 P/E ratio at 44.5 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialty Chemicals

	1st Jan change	Capi.	ESG Refinitiv
ALBEMARLE CORPORATION	-10.58%	15.18B	C+
ECOLAB INC.	+17.29%	66.43B	A-
SIKA AG	+2.30%	49.89B	A-
GIVAUDAN SA	+18.17%	41.88B	B+
FUJIFILM HOLDINGS CORPORATION	+20.88%	26.48B	A-
EMS-CHEMIE HOLDING AG	+10.87%	19.68B	C+
CELANESE CORPORATION	+0.19%	17B	B+
POSCO FUTURE M CO., LTD.	-21.87%	16.12B	A-
SYMRISE AG	+1.97%	15.28B	B+
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-20.34%	13.7B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes